You are here: Industry Insights > Baricitinib

News List

Lilly signs licensing agreements with Dr Reddy’s, MSN Labs and Torrent Pharma for Baricitinib expresspharma
May 14, 2021
On May 10, Lilly had also announced the signing of three Voluntary License Agreements with Cipla, Lupin and Sun Pharma Industries.
Lilly signs licensing agreements with Cipla, Lupin and Sun Pharma for Baricitinib in India expresspharma
May 11, 2021
Eli Lilly and Company announced that it has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries, who are collaborating with Lilly ...
Cipla signs licensing deal with Lilly to manufacture and commercialise baricitinib in India expresspharma
May 10, 2021
Baricitinib was issued a restricted emergency use approval by CDSCO to treat COVID-19.
NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment expresspharma
May 07, 2021
Baricitinib, in combination with Remdesivir, is used for treatment of COVID-19-positive patients.
Eli Lilly accelerates baricitinib’s availability in India expresspharma
May 07, 2021
Eli Lilly and Company has announced new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world.
EMA to assess if Olumiant should be authorised for hospitalised COVID-19 patients europeanpharmaceuticalreview
May 06, 2021
The EMA will conduct an accelerated assessment and issue its decision on whether Olumiant (baricitinib) can be used in hospitalised COVID-19 patients by July.
Baricitinib enhances hair regrowth for alopecia areata patients europeanpharmaceuticalreview
April 22, 2021
New Phase III data shows once daily treatment with baricitinib significantly increases hair regrowth in adult patients with severe alopecia areata.
Lilly, Incyte's Olumiant fails in COVID-19 trial pharmatimes
April 13, 2021
A Phase III trial of Eli Lilly and Incyte's baricitinib has failed to meet its primary endpoint in patients hospitalised with COVID-19.
Lilly, Incyte report trial results of baricitinib in Covid-19 patients pharmaceutical-technology
April 09, 2021
Eli Lilly and Incyte have reported that the Phase III COV-BARRIER study of baricitinib failed to meet statistical significance on the primary endpoint of progression to non-invasive ventilation or invasive mechanical ventilation or death in ...
New Progress in the Hair Loss Prevention Drug Market: JAK Inhibitor Baricitinib Reaches Phase 3 Clinical Primary Endpoint PharmaSources.com
March 26, 2021
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).

Previous page 1 2 3 4 5 Next page